FTC Orders Meyers’ Cocktail Seller Aaron Roberts, aka Aaron Keith, To Stop

The Federal Trade Commission, or FTC, announced Thursday that it had charged Aaron Keith, whose legal name is Aaron Roberts, with hawking bogus remedies (including his version of Meyers’ cocktail) for serious medical conditions like cancer, heart failure and certain neurodegenerative disorders.

Aaron Keithis ordered by FTC to stop claiming his version on the Meyers cocktail can treat cancer.

FTC takes aim at “iV Cocktail” therapy seller Aaron Keith Roberts.

Roberts company, A & O Enterprises and his DBAs, iV BARS Incorporated and iV BARS are accused of preying on seriously ill people by charging up to $250 for “treatments” that were actually just water with some herbs, vitamins and minerals added to it. The treatments were, says the FTC, just “simple mixtures” with little to no actual scientific support behind them.

What The “Meyers’ Cocktail” Is

Intravenous and intramuscular “therapies” are nothing new but certain mixtures–like the so-called Meyers’ cocktail–appear to be gaining in popularity among advocates (and consumers) of “natural” medicine.  But unlike a lot of other “alternative” therapies, Meyers’ cocktail treatments are based on the works of an actual physician.

John Meyers was a Baltimore doctor who, decades ago, advocated for the use of high-dose intravenous vitamins and minerals. In recent years, celebrities, professional athletes and well-known health bloggers have joined the bandwagon.

But such “therapies” are not without controversy. There is scant scientific research on them and virtually none supporting their use for conditions like cancer, diabetes and multiple sclerosis.

And that’s where the FTC comes in. Its order against Aaron Roberts will bar him from making claims about cancer, heart failure, multiple sclerosis, diabetes, fibromyalgia or neurodegenerative disorders. It would also prohibit him from making claims of lasting health benefits and any other health claims not supported by double-blind, peer-reviewed studies.

“This enforcement action should send a clear message to the burgeoning iV therapy industry and sellers of all healthcare products,” said Joe Simons in the agency’s press release. “Health claims must be supported by competent and reliable scientific evidence.”

Simons is Chairman of the Federal Trade Commission.